FDA grants priority review for new indication of finerenone for patients with heart failure and with a left ventricular ejection fraction of ≥40% – Bayer
Bayer announced that the FDA has accepted its supplemental New Drug Application (sNDA) and granted Priority Review designation for finerenone for the treatment of adult patients with heart… read more.